secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001178913-25-001110
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio reports FY2024 net loss of $9.5M; cash $21M as of March 28, 2025
---------------------------------------------------------------------------

- Net loss $9.5M ($0.25 per share) vs $8.9M ($0.31 per share) in FY2023.
- Cash and equivalents $8.7M at Dec 31, 2024; $21M as of March 28, 2025 after new investments.
- R&D expenses flat at $4.5M; G&A increased to $5.1M from $4.4M.
- Entera and OPKO entered oral GLP-1/Glucagon license agreement; IND filing expected in 2025.
- EB613 Phase 3 study planned pending FDA surrogate endpoint qualification; SABRE ruling awaited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891325001110/0001178913-25-001110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891325001110/zk2532935.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-001110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer